| Prev Close | 187.09 |
| Day Low/High | 182.88 / 187.15 |
| 52 Wk Low/High | 176.36 / 242.99 |
Vertex Pharmaceuticals Incorporated (VRTX)
183.52
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 259.43B |
| Market Cap | 48.54B |
| P/E Ratio | 23.27 |
| Div & Yield | N.A. (N.A) |
Closing Bell: Barclays Bets on Alphabet Growth; Dow Falls, S&P 500 and Nasdaq Rise
A rally in crude oil gave rise to the energy sector in a mixed day of trading.
Vertex Pharmaceuticals Reaches Upside Price Target
Base building pays off.
What You Must Know About Cystic Fibrosis Drug CTP-656
Acquiring CTP-656 from Concert Pharmaceuticals will only cost Vertex around $250 million.
Activist Investors Shake Up the Boards at Tiffany & Bristol-Myers Squibb
Jana Partners are placing three members on Tiffany's board.
Vertex Pharmaceuticals to Rely on Acquisitions to Diversify Its Business
Vertex Pharmaceuticals will be weighing future acquisitions and partnerships to broaden is focus beyond cystic fibrosis.
Vertex Pharmaceuticals Sees Sales of Cystic Fibrosis Drug Lower Than Expected
Vertex Pharmaceuticals provided new financial guidance for 2017 on Sunday.
Here's What to Look for at the J.P. Morgan Healthcare Conference
The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.
Cramer: Reviewing S&P's Hit-and-Miss Parade
Even among the losers, buys are scarce.
More Base Building Ahead for Vertex Pharmaceuticals
Buy signals have not lasted more than two months, so far.
Bullish and Bearish Chart Reversals
What stocks have changed direction in the past week.
5 Health Care Stocks Set to Bounce
These stocks are down some 20% over the last 30 months and look ripe for a rise.
A 'Semi-Charmed' Kind of NXPI Call Spread
It might be best to make this a late-afternoon purchase.
Cramer: How Did the Stock Market Get So Unwieldy?
The answer is that new data came out.
Charts Say Vertex Could Recover
The rate of decline slowed into the base, just what chartists like to see.
Stocks With Significant High Activity: the First Four Groups
There are some good buying ideas among these stocks.
Corbus Ready to Take Cystic Fibrosis Drug the Distance Says CEO
It’s been a hot M&A market for biotech companies developing treatments for rare diseases.
Can Biotechs' Relative Strength Be Trusted? 6 Stocks to Watch
Sector may not be as bulletproof as we thought.
Cramer: I Like Receptos and Radius, as Well as the Four Horsemen
Jim Cramer answers viewers' stock questions from the floor of the New York Stock Exchange.
Picasso Painting Sells for a Record $179 Million Dollars at Auction
A Picasso Painting Fetched $179 million dollars at an auction at Christie's Monday night, the most ever paid for a work of art at auction.
3 Fantastic Pharmaceutical Stocks: Abbvie, Vertex and Biogen
AbbVie is a cheap stock and worries about competition immediately hurting its rheumatoid arthritis drug Humira are overblown, said John Schroer, Portfolio Manager for the AllianzGI Health Sciences Fund.
Earnings and Marriage Season
Biotech companies are saying, "I do."
